raltegravir + famotidine

**raltegravir + famotidine** is a combination of two drugs: raltegravir, an HIV-1 integrase inhibitor used as part of antiretroviral therapy for HIV infection, and famotidine, an H2 histamine receptor antagonist used primarily for reducing gastric acid secretion in conditions like gastroesophageal reflux disease and peptic ulcer. Raltegravir blocks the strand transfer activity of HIV-1 integrase, preventing viral replication and integration into the host genome. Famotidine acts by selectively inhibiting histamine at H2 receptors of gastric parietal cells, decreasing acid production. Co-administration of famotidine and raltegravir increases the absorption rate and plasma levels of raltegravir, but this increase is not clinically significant, and no dose adjustment is recommended when used together[1][2][3].